Immunome Analyst Ratings
Immunome's Promising Pipeline and Strategic Positioning Affirm Buy Rating
TD Cowen Sticks to Their Buy Rating for Immunome (IMNM)
Immunome Analyst Ratings
JPMorgan Starts Immunome With Overweight Rating, $24 Price Target
Analysts Offer Insights on Healthcare Companies: Immunome (IMNM), Dyne Therapeutics (DYN) and Dexcom (DXCM)
Immunome Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), AbbVie (ABBV) and Immunome (IMNM)
Immunome Analyst Ratings
Immunome (IMNM) Receives a Buy From Wedbush
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), United Therapeutics (UTHR) and Immunome (IMNM)
TD Cowen Reaffirms Their Buy Rating on Immunome (IMNM)
Leerink Partners Sticks to Their Buy Rating for Immunome (IMNM)
Immunome Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Immunome (IMNM) and Simulations Plus (SLP)
Immunome Analyst Ratings
Wedbush Starts Immunome With Outperform Rating, $12 Price Target; Has Positive View for Early-Stage Pipeline of Targeted Cancer Therapies
Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Spruce Biosciences (SPRB) and Immunome (IMNM)
Cantor Fitzgerald Reiterates Overweight on Immunome, Maintains $8 Price Target
Chardan Capital Sticks to Its Buy Rating for Immunome (IMNM)
No Data